Group items tagged

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

A leading pharmacist and member of the Royal Pharmaceutical Society (RPS) Scottish Pharmacy Board has been chosen to share her experiences of working in a community pharmacy in Scotland. Catriona Sinclair FRPharmS will speak at a roundtable entitled 'International Experiences in Professional Pharmaceutical Health Services' in Madrid on Thursday (May 5). Catriona, who owns and runs a pharmacy in the Highlands, is expected to give her take on community pharmacies' significant contribution towards achieving improved health outcomes and reducing health inequalities for local populations in Scotland. As an active independent prescriber, she is at the cutting edge of the profession in Scotland. Speaking ahead of her visit to Madrid, Catriona said: "I'm honoured to have the opportunity to collaborate with pharmacists from across Europe, and to share my experiences of working as a community pharmacist in Scotland.

Errors of any kind in medical settings can have dire consequences for patients and healthcare systems. Unfortunately, negligence, misdiagnosis, and medication errors aren't uncommon in the UK. In this article, we discuss the nature of medication errors in the NHS, outline potential causes, and delve into how and why technology could be turning the tide on the issue. Prevalence and consequences of medication errors Medication errors are incidents involved with the administering, prescribing, dispensing or monitoring of medicine to patients. It can happen at many different steps in the healthcare process and by any medical professional in the system. Many cases are avoidable. According to analysis from BMJ, there are an estimated 237 million medication errors made in England every year. The majority of these are minor errors, but 1 in 4 cases has the potential to cause moderate to serious harm to patients. Not only do these errors cost the NHS significantly, at almost £100 million every year, but there is a shocking cost to public health. Lives are being lost because of medication errors which is unforgivable and tragic for the families involved. Drains on NHS resources have widespread impacts on public health and the operations of healthcare organisations up and down the country. Individual errors and mistakes may seem inconsequential (in minor cases), but they all add up in the big picture to a significant concern for policymakers.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery. Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the drugmaker said. The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy. AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health authorities globally. Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign substances in the body. The treatment generated $2.41 billion in 2021 sales.

The National Institute of Health and Care Excellence has recommended that surgeons working in hospitals with limited or no access to a radiopharmacy department could now use Magtrace and Sentimag as an option to locate sentinel lymph nodes in people with breast cancer. The recommendation in draft NICE medical technology guidance could see a change in NHS standard care for the first time in years. The technology could also mitigate the reliance on radioactive isotope tracers shipped in from outside Great Britain. The magnetic liquid tracer - Magtrace - is a non-radioactive dark brown liquid. It is both a magnetic marker and a visual dye. The Magtrace is injected into the tissue around a tumour. The particles are then absorbed into the lymphatic system, following the route that cancer cells are most likely to take when they spread from the primary tumour and become trapped in sentinel lymph nodes. The Sentimag probe moves over the skin emitting sounds of different pitches as it passes over the Magtrace tracer, in a similar way to a metal detector locating metal in the ground. The nodes often appear dark brown or black in colour, which also helps with identification.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

Thirteen people were arrested following raids at four drug manufacturing units in the Indian states of Gujarat and Rajasthan, resulting in the seizure of mephedrone valued at Rs 230 crore (approximately 22.30 million GBP), according to a news agency report. The Gujarat Anti-Terrorist Squad (ATS) and Narcotics Control Bureau conducted the raids jointly on Friday, prompted by a tip-off received by the ATS indicating that Ahmedabad resident Manoharlal Enani and Kuldeepsinh Rajpurohit from Rajasthan had set up mephedrone manufacturing units, PTI reported on Saturday, quoting an official. As stated in an ATS release obtained by the news agency, the raids were conducted at the units in Sirohi and Jodhpur in Rajasthan and Piplaj village in Gandhinagar and Bhaktinagar industrial area of Amreli district in Gujarat. "The ATS recovered 22.028 kilograms of mephedrone (in solid form) and 124 kilograms of liquid mephedrone, collectively valued at Rs 230 crore(approximately 22.30 million GBP). "Rajpurohit was nabbed during the raid in Gandhinagar and Enani was held from Sirohi," it said.

The Indian government has suspended manufacturing in over 40 pharmaceutical companies based on a risk-based assessment conducted earlier in the year across 162 firms, according to the data provided by Union Health Minister Mansukh Mandaviya in Parliament on Thursday (Aug. 10). "Overall, a sum of 143 show-cause notices has been issued," Mandaviya said. There have been numerous recent incidents involving accusations from foreign countries regarding the contamination of syrups, eye drops, and ointments manufactured in India. Countries such as the Gambia, Uzbekistan, and Cameroon have linked the deaths of 70, 18, and six children, respectively, to cough syrups contaminated in India. Licenses for specific products have been either temporarily suspended or fully revoked for an additional 66 companies. In one case, an FIR has been registered, and in 21 cases, warning letters have been issued following inspections by both the Central Drugs Standard Control Organization and State authorities, the Minister added. Meanwhile, the Indian government has mandated rigorous testing for cough syrups before export. Starting June 1, any cough syrup must possess a government laboratory-issued certificate of analysis before being exported, the government said in a notice dated May 22.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

The International Pharmaceutical Federation (FIP) in a report of a meeting of an international insight board published on Friday (27 January) highlighted the potential for pharmacists to close the existing gender gap in pain management. The insight board, assembled by FIP in Seville, Spain, in September 2022, was co-chaired by FIP vice president Professor Parisa Aslani. "Research indicates that pain experienced by women is underestimated and undertreated. Alarmingly, in addition to receiving less effective pain relief, evidence suggests that women with pain are more likely to be prescribed antidepressants," Prof. Aslani said. The insight board attributed much of this "gender pain gap" to implicit biases and put forward the view that pharmacy curricula and continuous professional development programmes must be able to provide adequate self-awareness and training to enable pain management without any bias. It also suggested ways in which pharmacists could be supported in addressing the gender pain gap in their practice.

Mental health issues are very common, and one in four people will experience a mental health problem in their lifetime. Unfortunately, many people do not seek treatment because they are embarrassed or ashamed. However, there is no need to be ashamed - mental health problems are just like any other medical condition. Treatment options include therapy, medication, and lifestyle changes. In this blog post, we will discuss the top ways medications can help in treating mental health issues. We will also dispel some of the myths about mental health medications. MENTAL HEALTH MEDICATIONS CAN REDUCE ANXIETY AND DEPRESSION Mental health medications can be very effective in treating mental illness. In fact, they can be just as effective as medications for physical health conditions. Mental health medications can help to reduce symptoms, improve functioning, and prevent relapses. They are also legal psychedelic medicine that have been shown to be helpful in treating mental illness. For example, ketamine has been shown to be effective in treating depression, anxiety, and post-traumatic stress disorder. Some people worry that taking mental health medication will make them feel like a different person. However, this is not the case. Mental health medications can help you to feel like yourself again. They can also help you to function better in your everyday life.

Northern Ireland's chief pharmaceutical officer paid a visit to a community pharmacy in Belfast on Monday (November 7) - marking the end of this year's Ask Your Pharmacist week, an annual public awareness campaign launched by the National Pharmacy Association. Cathy Harrison interacted with patients and staff in the pharmacy before recording a video to promote NI's 'Pharmacy First' service in which she described community pharmacies as "one of the front doors to the health service" with over 500 outlets located across the country. "In our community pharmacies you can always rely on friendly staff, medicines expertise, and walk-in access to face-to-face advice," she said. First launched in Scotland, the NHS Pharmacy First service enables patients to have a consultation with a pharmacist for advice on minor ailments. Ms Harrison also drew attention to community pharmacy's role in cancer awareness and helping people to quit smoking, as well as managing patients with urinary tract infections, in addition to playing their part in delivering Covid-19 and flu vaccinations.

The new board of the National Pharmacy Association (NPA) has adopted 10 principles for transforming the contractual framework in England. The board met for the first time in April, believes that the current Community Pharmacy Contractual Framework is failing NPA members, the wider sector, the NHS, Government and patients. The association's new vice chair, Jay Badenhorst, said: "We can't wait until the current framework limps to its finish line in 2024 before giving serious thought to the new race we must all run in the future." "Before negotiations for a new contract begin in earnest, we want to make our position clear to all of those who will be involved in its development. Years more of the same would be totally unacceptable. Tinkering at the edges of the current arrangements as the basis for a new deal could not achieve the transformation that is needed." Former chair of the NPA, Andrew Lane, listed some of the principles in a speech to industry leaders in January, but this is the first time the approach has been agreed in its entirety, following months of testing with NPA members.

Are you looking to start a career in the medical field but don't know where to begin? There are many different paths to choose from when it comes to entering the medical profession. It can be daunting trying to figure out which one is right for you. But with some research, planning, and dedication, you can find your way into this rewarding and fulfilling industry. Here are 8 tips that will help get you started on your journey toward becoming a successful healthcare professional. 1. ONLINE PROGRAMS If you have already decided on a career path and need to obtain additional qualifications or knowledge, there are many online programs available for medical professionals. These courses provide students with the opportunity to learn from home and gain experience in their chosen field without sacrificing the quality of education. You can find an online medical assistant programs, medical biller and coding programs, lab technician training, and more. It's important to research each program and make sure it's accredited before enrolling. While online programs may not offer the same hands-on experience as a traditional school, they can be an affordable and convenient way to get your foot in the door. 2. VOLUNTEERING OR WORKING IN A CLINICAL SETTING Volunteering or working part-time in a clinical setting is an excellent way to gain experience and decide if the medicine is the right profession for you. Even volunteer work can provide invaluable insight into how the medical field works, allowing you to network with professionals, observe procedures and treatment methods, and develop skills from patient interaction. Additionally, any volunteer work or job experience related to healthcare that appears on your resume establishes you as a serious candidate for a career in medicine. While you are likely to find many volunteer opportunities, be sure to do your research and only take positions in reputable organizations.

Community pharmacy workforce is in a fragile condition and faced a shortfall of 3,000 pharmacists in England over a period of five years, a recent research conducted by the Company Chemists' Association (CCA) has revealed. It noted that over the last five years, the net growth of community pharmacists in England a year stood at 733. This is much lower than the required average growth of 1,025, based on data reported by the Health Education England workforce survey from 2021. Acknowledging the discrepancies in the data calculation, the paper published by the association has used "the best available data" to highlight recent changes to the community pharmacy workforce in England. The report noted that despite an increase in the number of pharmacists, many contractors reported an increase in pharmacist vacancies. They also reported a significant increase in locum hourly pay rates, indicating demand exceeds supply.

Professor Michael Gordon Scott and Professor Charlotte Anne Skitterall have been recognised in the New Year Honours list 2023 for their 'service to pharmacy'. Professor Scott Director, Medicines Optimisation Innovation Centre was one among the 1,107 people to received MBE for his 'service to pharmacy' in Northern Ireland. In 1994 he established the first academic practice unit in the province in conjunction with the Queens University of Belfast. In 2004 he was made a fellow of the Pharmaceutical Society of Northern Ireland. In June 2009 he was made an honorary Professor of Pharmacy Practice at QUB. Professor Skitterall, Group Chief Pharmacist, Manchester University NHS Foundation Trust received MBE for 'services to Pharmacy'. Last year, she was appointed as a Fellow of the Royal Pharmaceutical Society. "I think it was awarded in recognition of the work I have done as chair of the National Medicines Optimisation Clinical Reference Group. I also supported the National Pharmacy Task and Finish Group for Covid Vaccine deployment," she commented. This year, dozens of NHS staff have been recognised in the New Year Honours list ahead of the health service's 75th birthday.

Tough times for community pharmacies in England are far from over as the industry continues to grapple with major gaps in the workforce. Even though the latest figures released by the Health Education England (HEE) Community Pharmacy Workforce Survey 2021 showed doubling of pharmacist vacancy rate in England to 8 per cent between 2017 and 2021, it flagged the contractors' difficulty level in filling up these positions. The survey report showcased changes in the size and make-up of the community pharmacy workforce since the last survey conducted in 2017. It revealed that 56 per cent of pharmacy contractors reported high difficulty level in recruiting pharmacists, up from 21 per cent in the earlier survey. Moreover, a greater proportion - 60 per cent of contractors found filling up the pharmacy technician role 'fairly' or 'very' difficult. Other roles in the sector considered difficult to fill included accuracy checkers and trained dispensing assistants, both at 58 per cent.

RPS Scotland has named Fiona McIntyre as its new Policy and Practice Lead. With a background in hospital pharmacy, McIntyre will be responsible for policy development and professional support at RPS Scotland, and is set to assume her new role in early October. McIntyre will assume a leadership role for specific projects across Great Britain, collaborating with the Policy and Practice Leads in England and Wales, RPS Scotland said in a statement. Her responsibilities include representing pharmacists in working groups and meetings, engaging with pharmacists and pharmacy organisations, and supporting the RPS Director for Scotland. "During my career in NHS Scotland, I have advocated for pharmacy teams whenever possible," said McIntyre. "I am passionate about the profession's role in the safe and effective use of medicines, and I'm privileged to join the RPS. I look forward to promoting pharmacy in Scotland and helping our profession reach its full potential." "I'm pleased that Fiona will be joining the RPS Scotland team as our policy lead," said Laura Wilson, Director for RPS Scotland. "Fiona's experience will be invaluable to the role, and the whole team looks forward to her starting with us in October."